Homoeriodictyol

Homoeriodictyol

SCHEMBL2307702

COc1cc(C2CC(=O)c3c(O)cc(O)cc3O2)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 6/20 1.00
CYP1A2 P05177 6/20 1.00
CYP1B1 Q16678 6/20 1.00
POLB P06746 2/20 1.00
CYP19A1 P11511 7/20 0.83
CYP3A4 P08684 5/20 0.83
TP53 P04637 3/20 0.83
CA12 O43570 3/20 0.83
CA4 P22748 3/20 0.83
CYP2C19 P33261 3/20 0.83
CA7 P43166 3/20 0.83
HSD17B10 Q99714 3/20 0.83
MAPT P10636 3/20 0.83
ALDH1A1 P00352 3/20 0.83
XDH P47989 2/20 0.83
HPGD P15428 2/20 0.83
PKM P14618 2/20 0.83
MAPK1 P28482 2/20 0.83
CYP2C9 P11712 2/20 0.83
DPP4 P27487 2/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Homoeriodictyol SCHEMBL30383489 1.00 CYP1A1 (1.00) CYP1A1CYP1A2CYP1B1POLBCYP19A1
Homoeriodictyol SCHEMBL39497 1.00 CYP1A1 (1.00) CYP1A1CYP1A2CYP1B1POLBCYP19A1
Homoeriodictyol SCHEMBL30016824 1.00 CYP1A1 (1.00) CYP1A1CYP1A2CYP1B1POLBCYP19A1
Homoeriodictyol SCHEMBL29411740 1.00 CYP1A1 (1.00) CYP1A1CYP1A2CYP1B1POLBCYP19A1
Homoeriodictyol SCHEMBL1505910 0.99 CYP1A1 (0.98) CYP1A1CYP1A2CYP1B1POLBCYP19A1
Homoeriodictyol SCHEMBL2024548 0.99 CYP1A1 (0.98) CYP1A1CYP1A2CYP1B1POLBCYP19A1
Homoeriodictyol SCHEMBL2019518 0.99 CYP1A1 (0.98) CYP1A1CYP1A2CYP1B1POLBCYP19A1
Homoeriodictyol SCHEMBL7535609 0.99 CYP1A1 (0.98) CYP1A1CYP1A2CYP1B1POLBCYP19A1
Homoeriodictyol SCHEMBL3422048 0.98 CYP1A1 (0.95) CYP1A1CYP1A2CYP1B1POLBCYP19A1
SCHEMBL31028356 0.93 CYP19A1 (0.87) CYP1A1CYP1A2CYP1B1POLBCYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021042001-A1 COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES Natural Extraction Systems, LLC (US) 2021-03-04 WO claimed
EP-1258200-B1 Use of hydroxyflavones for masking of bitterness, and food and pharmaceutical compositions comprising an effective amount thereof SYMRISE GMBH & CO KG (DE) 2005-02-16 EP claimed
US-20020188019-A1 Use of hydroxyflavanones for masking bitter taste SYMRISE AG (DE) 2002-12-12 US claimed
EP-1258200-A2 Use of hydroxyflavones for masking of bitterness, and food and pharmaceutical compositions comprising an effective amount thereof HAARMANN & REIMER GMBH (DE) 2002-11-20 EP claimed
EP-4699452-A2 OBTAINING A VOLATILE FRACTION FROM JUICES OR ALCOHOLIC BEVERAGES Symrise AG (DE) 2026-02-25 EP disclosed
US-20260041109-A1 ROBUST FLAVOR EMULSIONS INT FLAVORS & FRAGRANCES INC (US) 2026-02-12 US disclosed
EP-3836799-B1 OBTAINING A VOLATILE FRACTION FROM JUICES OR ALCOHOLIC BEVERAGES SYMRISE AG (DE) 2025-11-26 EP disclosed
US-12419815-B2 Microcapsule compositions stabilized with viscosity control agents INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 2025-09-23 US disclosed
US-12357547-B2 Compositions containing microcapsules INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 2025-07-15 US disclosed
US-12324452-B2 Delivery systems and methods of preparing the same INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 2025-06-10 US disclosed
US-12274771-B2 Polyurea capsule compositions INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 2025-04-15 US disclosed
US-12030326-B2 System and method for printing and drying flavors and fragrances INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 2024-07-09 US disclosed
US-7268115-B2 Cyclic peptides; three-dimensional structures; screening; anticancer agents; angiogenesis inhibitors; drug delivery ADHEREX TECHNOLOGIES, INC. (CA) 2007-09-11 US disclosed
EP-1258200-B1 Use of hydroxyflavones for masking of bitterness, and food and pharmaceutical compositions comprising an effective amount thereof SYMRISE GMBH & CO KG (DE) 2005-02-16 EP disclosed
WO-2004041804-B1 TECHNICAL PROCESS FOR ISOLATING HOMOERIODICTYOL SYMRISE GMBH & CO KG (DE) 2005-01-27 WO disclosed
WO-2004041804-A3 TECHNICAL PROCESS FOR ISOLATING HOMOERIODICTYOL SYMRISE GMBH & CO KG (DE) 2004-12-09 WO disclosed
WO-2004041804-A2 TECHNICAL PROCESS FOR ISOLATING HOMOERIODICTYOL SYMRISE GMBH & CO. KG (DE) 2004-05-21 WO disclosed
WO-2004041804-A2 TECHNICAL PROCESS FOR ISOLATING HOMOERIODICTYOL SYMRISE GMBH & CO. KG (DE) 2004-05-21 WO disclosed
US-20020188019-A1 Use of hydroxyflavanones for masking bitter taste SYMRISE AG (DE) 2002-12-12 US disclosed
EP-1258200-A2 Use of hydroxyflavones for masking of bitterness, and food and pharmaceutical compositions comprising an effective amount thereof HAARMANN & REIMER GMBH (DE) 2002-11-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12357547-B2 Compositions containing microcapsules COPE, SAAL1, AUP1 CYP1A1 4650/4885CYP1A2 4690/4885CYP1B1 4578/4885
US-12324452-B2 Delivery systems and methods of preparing the same MAL2, TAS2R42, TAS2R31 CYP1A1 374/4885CYP1A2 414/4885CYP1B1 583/4885
US-12419815-B2 Microcapsule compositions stabilized with viscosity control agents ACR, ALG1, MLEC CYP1A1 4831/4885CYP1A2 4836/4885CYP1B1 4744/4885
US-20020188019-A1 Use of hydroxyflavanones for masking bitter taste TAS2R60, TAS2R50, TAS2R30 CYP1A1 1504/4885CYP1A2 630/4885CYP1B1 1772/4885
US-12274771-B2 Polyurea capsule compositions PUF60, UMPS, PCBP1 CYP1A1 4767/4885CYP1A2 4802/4885CYP1B1 4641/4885
US-20260041109-A1 ROBUST FLAVOR EMULSIONS ACACA, FABP4, CUTA CYP1A1 2995/4885CYP1A2 2577/4885CYP1B1 2649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.